

DAFTAR PUSTAKA

- Abidullah, Hussain H., Shujat A., Kamal Z. and Ullah S., 2013, Pharmacotherapeutical Study of Peptic Ulcer Disease, *Impact Journal*, 1 (3), 29–36.
- Alfiawati N., 2014, Evaluasi Penggunaan Obat Pada Pasien Tukak Peptik Di Instalasi Rawat Inap RSUP Dr. Soeradji Tirtonegoro Klaten Tahun 2014, *Skripsi*, Fakultas Farmasi, Universitas Muhammadiyah Surakarta, Surakarta.
- Alldredge B.K., Corelli R.L., Ernst M.E., Guglielmo B.J., Jacobson P.A., Kradjan W.A. and Williams B.R., 2013, *Gastrointestinal Disorders*, Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of Drugs, Wolters Kluwer Lippincott Williams & Wilkins, pp. 669–679.
- Al-marsoumi and Jabbo, 2013, Risk factors in perforated peptic ulcer disease : Incidence and relation to morbidity and mortality, *Mustansiriya Medical Journal*, 12 (1), 35–44.
- Ansari J.A., 2010, Drug Interaction and Pharmacist, *Journal of young pharmacists : JYP*, 2 (3), 326–331.
- Avunduk C., 2008, *Manual Of Gastroenterology : Diagnosis and Therapy*, Fourth Edition., Wolters Kluwer Lippincott Williams & Wilkins, Philadelphia.
- Baxter K., 2008, *Stockley's Drug Interactions*, Eighth Edition., Pharmaceutical Press, London.
- Berardi R.R. and Welage L.S., 2008, Pharmacotherapi : A Pathophysiologic Approach, dalam *Gastrointestinal Disorders*, Mc-GrawHill, New York, pp. 569–583.
- British National Formulary, 2011, British National Formulary 61, dalam *Gastrointestinal System*, BMJ Group and the Royal Pharmaceutical, London.
- Chan W.H., Khin L.W., Chung Y.F.A. and Wong W.K., 2011, Randomized Controlled Trial of Standard Versus High-dose Intravenous Omeprazole After Endoscopic Therapy in High-risk Patients With Acute Peptic Ulcer Bleeding, *British Journal of Surgery Society Ltd*, 98(5) Terdapat di: <https://www.ncbi.nlm.nih.gov/pubmed/21305536>.
- Cipolle R.J., Strand L.M. and Morley P.C., 1998, *Pharmaceutical Care Practice*, McGraw-Hill: Health Professions Division, United States of America.
- Cipolle R.J., Strand L.M. and Morley P.C., 2004, *Pharmaceutical Care Practice : The Clinician's Guide*, Second Edition., Mc-GrawHill Companies.

- Drug Administration and Control Authority, 2007, National Drug Formulary of Ethiopia, 5–7. Terdapat di: http://www.who.int/medicines/areas/coordination/ethiopia_formulary.
- Desta Z., Soukhova N. V. and Flockhart D.A., 2001, Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A, *Antimicrobial Agents and Chemotherapy*, 45 (2), 382–392.
- Djojoningrat D., 2001, Dispepsia Fungsional, Dalam *Buku Ajar Ilmu Penyakit Dalam*, Balai Penerbit FKUI, Jakarta, pp. 153–157.
- Drepper M.D., Spahr L. and Frossard J.L., 2012, Clopidogrel and proton pump inhibitors -where do we stand in 2012?, *World journal of gastroenterology : WJG*, 18 (18), 2161–2171.
- Faull R., 2007, Prescribing in Renal Disease, *Australian Prescriber*, 30 (1), 17–20.
- Food and Drug Administration, 2011, FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs), *U.S. Department of Health and Human Services* Terdapat di: <http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm> [Diakses pada October 16, 2016].
- Flockhart, 2001, Methods of Drug Interaction Studies, 5. Terdapat di: <http://www.nihs.go.jp/phar/pdf/DiGIEngFinal011209>.
- Halczli A. and Woolley A.B., 2013, Medication underdosing and underprescribing: important issues that may contribute to polypharmacy and poor outcomes, *Formulary Journal Outcomes*, 1–4.
- Helmyati S., Rahmawati N.F., Purwanto and Yuliati E., 2014, *Buku Saku Interaksi Obat dan Makanan*, Gajah Mada University Press, Yogyakarta.
- Hirlan, 2001, Gastritis, Dalam *Buku Ajar Ilmu Penyakit Dalam*, Balai Penerbit FKUI, Jakarta, pp. 127–131.
- Kementrian Kesehatan Republik Indonesia, 2010, *Profil Kesehatan Indonesia Tahun 2009*, Kementrian Kesehatan Republik Indonesia, Jakarta.
- Kementrian Kesehatan Republik Indonesia, 2011, *Pedoman Interpretasi Data Klinik*, Jakarta.
- Joenoos N.Z., 2009, *Ars Prescribendi: Resep yang Rasional*, Airlangga University Press, Surabaya.
- Kigen G., Kimaiyo S., Nyandiko W., Faragher B., Sang E., Beatrice, Jakait, Owen A., Back D., Gibbons S., Seden K. and Khoo S.H., 2011, Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort, *PLoS ONE*, 6 (2), 2.

- Kolesar J. and Vermeulen L., 2016, *Top 300 Pharmacy Drug Cards*, Mc Graw Hill Education, New York.
- Lacy C.F., Armstrong L.L., Goldman M.P. and Lance L.L., 2009, *Drug Information Handbook*, 17th Edition., Lexi-Comp for American Pharmacists Association.
- Lockrey G. and Lim L., 2011, Peptic Ulcer Disease in Older People, *Journal of Pharmacy Practice and Research*, 41 (1), 58–60.
- Lucida H., Trisnawati R. and Suardi M., 2011, Analisis Aspek Farmakokinetika Klinik Pasien Gagal Ginjal Pada IRNA Penyakit Dalam RSUP DR. M. Djamil Padang Fakultas Farmasi Universitas Andalas Padang, *Jurnal Sains dan Teknologi Farmasi*, 16 (2), 144–152.
- Matsui H., Shimokawa O., Kaneko T., Nagano Y., Rai K. and Hyodo I., 2011, The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and intestine, *J. Clin. Biochem. Nutr*, 48 (2), 107–111.
- Mohebbi L. and Hesch K., 2009, Stress ulcer prophylaxis in the intensive care unit, *Baylor University Medical Center Proceedings*, 22 (4), 373–376.
- Neal M.J., 2007, *At a Glance: Farmakologi Medis*, Edisi Kelima., Penerbit Erlangga, Jakarta.
- Nita Y., 2004, *Manajemen Farmasi*, Airlangga University Press, Surabaya.
- Pharmaceutical Care Network Europe, 2006, *PCNE Classification for Drug Related Problem*, Pharmaceutical Care Network Europe Foundation.
- Priyanto, 2009, *Farmakoterapi & Terminologi Medis*, Penerbit : Lembaga Studi dan Konsultasi Farmakologi (Leskonfi), Jakarta.
- Sanusi I.A., 2011, *Buku Ajar Gastroenterologi*, Edisi Kesatu., InternaPublishing Pusat Penerbitan Ilmu Penyakit Dalam, Jakarta Pusat.
- Setiawati A., 2008, *Farmakologi dan Terapi*, edisi 5., Departemen Farmakologi dan Terapeutik Fakultas Kedokteran - Universitas Indonesia, Jakarta.
- Siddique R.A.H., 2014, Prevalence of Peptic Ulcer Disease Among the Patients With Abdominal Pain Attending the Department of Medicine in Dhaka Medical College Hospital, Bangladesh, *IOSR Journal of Dental and Medical Sciences*, 13 (1), 5–9.
- Tas I., Ulger B.V., Onder A., Kapan M. and Bozdog Z., 2015, Risk Factors Influencing Morbidity and Mortality in Perforated Peptic Ulcer Disease, *Turkish Surgical Association*.

- Tatro D.S., 2012, *Drug Interaction Facts 2012: The Authority on Drug Interactions*, Wolters Kluwer Health, California.
- Thorsen K., Soreide J.A., Kvaloy J.T., Glomsaker T. and Soreide K., 2013, Epidemiology of Perforated Peptic Ulcer: Age - and Gender Adjusted Analysis of Incidence and Mortality, *World Journal of Gastroenterology*, 19 (3), 347–354.
- Vanderhoff B.T. and Tahboub R.M., 2002, Proton pump inhibitors: An update, *American Family Physician*, 66 (2), 273–278.
- Veterans Affairs Pharmacy Benefits, 2005, Criteria for Use of High-dose Oral Proton Pump Inhibitors, Terdapat di: <http://www.pbm.va.gov> [Diakses pada October 28, 2016].
- Wecker L., Crespo L.M., Dunaway G., Faingold C. and Watts S., 2010, *Brody's Human Pharmacology Molecular to Clinical*, Fifth Edition., Mosby Elsevier, Canada.